Management of PRES in Patients Receiving Pazopanib
Permanently discontinue pazopanib immediately if PRES develops 1.
Immediate Actions
When PRES is suspected in a patient on pazopanib, the following algorithmic approach should be followed:
1. Confirm the Diagnosis
- Obtain MRI immediately to confirm PRES, looking for characteristic T2-weighted hyperintensities showing vasogenic edema in bilateral parietal-occipital regions (though atypical patterns occur) 1
- Recognize the clinical presentation: headache, seizures, lethargy, confusion, blindness, and other visual/neurologic disturbances 1
- Note that mild to severe hypertension may be present but is not always the primary driver 1
2. Stop Pazopanib Permanently
The FDA label is unequivocal: permanently discontinue pazopanib in patients who develop PRES 1. This is non-negotiable—there is no dose reduction or rechallenge option for PRES with pazopanib, unlike some other toxicities where the drug may be withheld and resumed.
3. Implement Supportive Management
Blood Pressure Control:
- Very stringent blood pressure control is crucial 2
- Target mean arterial pressure optimization with antihypertensive agents as needed
- Monitor blood pressure continuously during the acute phase
Seizure Management:
- Initiate antiepileptic treatment immediately if seizures occur 2
- Maintain seizure precautions throughout recovery
- Benzodiazepines may be used for acute seizure control 2
Electrolyte Correction:
- Check and correct any electrolyte imbalances, particularly sodium disturbances 2
Expected Recovery Timeline
PRES is usually reversible with appropriate supportive management within 2 weeks 2. The condition typically shows complete clinical and radiologic resolution when recognized early and managed appropriately. Case reports confirm symptom improvement after pazopanib discontinuation 3, 4, 5.
Critical Pitfalls to Avoid
Do not attempt to rechallenge with pazopanib. The FDA label explicitly states permanent discontinuation 1, and the ESMO-EONS-EANO guideline notes that "reintroduction of the prior anticancer therapy has to be decided on an individual basis" for PRES generally 2—but given the FDA's specific directive for pazopanib and the potential for fatal outcomes, rechallenge is contraindicated.
Do not delay MRI. PRES can be misdiagnosed as stroke, encephalitis, or other acute neurological syndromes. MRI is the diagnostic gold standard and should not be delayed for CT alone, which may be normal 2.
Recognize early presentation. PRES can occur very early in pazopanib therapy—one case report documented PRES just 3 days after initiation 3. Maintain high clinical suspicion throughout treatment, particularly in the first 18 weeks when most adverse events occur.
Mechanism and Risk Context
Pazopanib, as a VEGF receptor tyrosine kinase inhibitor, disrupts normal endothelial function in the brain, leading to blood-brain barrier breakdown and vasogenic edema 4. Highly selective VEGFR-2 inhibitors like pazopanib show particularly strong PRES signals in pharmacovigilance data 6. Approximately 40% of pazopanib patients develop hypertension, which compounds PRES risk 1.
Alternative Cancer Therapy Considerations
Once PRES has resolved and the patient is neurologically stable, oncologic management must proceed without pazopanib. Discuss alternative systemic therapies with oncology based on the underlying malignancy (renal cell carcinoma or soft tissue sarcoma), as pazopanib cannot be safely reintroduced.